Healthcare Realty Trust

▲ Bull Case

• ◆Pipeline and occupancy deliver above expectations: same-store NOI sustains at 5%+ through 2027, redev pipeline delivers $30M annual NOI uplift by 2028, 2028 FFO/share reaches ~$1.85, P/FFO expands to 14–14.5x, implying bull price $26–28 (+30–40% total return inc. dividends).
• ◆Strategic transaction: Welltower or Healthpeak acquires HR at 15x FFO premium, given CEO Scott's peer relationships and Starboard's strategic-alternatives pressure, implying $26–27/share takeout (30% premium).
• ◆Dividend growth resumes 2027: First raise post-cut attracts income investors back to shareholder roster; multiple expansion follows re-broadening of investor base.

▼ Bear Case

• ◆Multiple compression: Cap rates widen to 6.5–7.0% if 10Y Treasury rallies to 5%+, REIT multiples compress 1–2 turns, NAV drops to $14.50–$15.50, P/FFO falls to 10.5x, implying bear price $17–19 (-7% to -17%).
• ◆Health system credit event: Medicaid cuts at $1T scale signed into law; CommonSpirit or top-5 tenant restructures, SS-NOI growth collapses to 2% in 2027–2028, FFO contracts to $1.55.
• ◆Dividend remains flat through 2028: Income investors continue rotation to DOC and WELL (5.5%+ and 3.0% yield); HR's 4.7% yield at $20.47 no longer the relative bargain it was at $18.

“The Street is debating whether the re-rating is complete or has further to run. Three Buys and three Holds at $19.67 average target (stock at $20.47) shows consensus pricing the easy upside as captured. Cantor Fitzgerald's implied 17x 2026E AFFO target is consistent with current ~16x, suggesting fair valuation post-rally. Bulls argue redevelopment, occupancy gains, dividend catalyst, and M&A optionality are not yet in numbers; HR can re-rate to 14x FFO ($23–24). Bears argue stock is at 16x AFFO already (above DOC's 11.3x and MOB sector 14.6x); further expansion requires perfect execution, benign rates, and Medicaid washout. Central disagreement: can execution sustainably justify higher multiple, or is risk/reward deteriorating at current price?”

• ◆Net debt/EBITDA reaches 5.0x (Q4 2026 likely)—re-rating trigger and rating upgrade discussion
• ◆Dividend increase announcement (late 2026/2027)—investor base broadens, multiple +0.5–1.0 turn
• ◆Q2/Q3 2026 same-store NOI sustains 5%+—validates Q1 2026 was not one-time, consensus revisions
• ◆Redev pipeline (~$300M) hits 9–12% returns (2027–2028)—+$0.06–0.08 FFO/share uplift

• ◆Interest rate shock and cap-rate widening (6.5–7.0%)—REIT multiples compress 1–2 turns, NAV declines to $14.50–$15.50
• ◆Medicaid cuts at full $1T scale—major tenant credit deterioration, SS-NOI growth drops to 2%, health-system expansion capex freezes
• ◆Second dividend cut or flat through 2028—income-investor flight, multiple re-rates to distressed 10–11x AFFO range
• ◆Disposition market closure or forced equity issuance—deleveraging stalls above 5.5x, refinancing pressure mounts